Results 141 to 150 of about 57,323 (255)

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy

, 2017
Zhuanglei Gao,1 Zhaoxia Li,2 Jieke Yan,3 Peilin Wang1 1Department of General Surgery, 2Department of Pediatrics, 3Department of Renal Transplantation, The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China ...
Li Z, Yan J, Wang P, Gao Z
core  

Drug Delivery With Metal–Organic Frameworks

Angewandte Chemie Novit, Volume 2, Issue 3, September 2026.
Metal–organic frameworks (MOFs) have recently entered human clinical trials for cancer radiotherapy, highlighting both the maturity and potential of MOFs as platforms for drug delivery. This minireview introduces the principles of MOF‐based drug delivery and discusses key opportunities and design challenges that will shape the next generation of these ...
Nathalie W. Tarabay, Alexander S. Evtushenko, Mohammad Reza Alizadeh Kiapi, Xu Chen, Katia Caamaño, Ljiljana Fruk, David Fairen‐Jimenez   +6 more
wiley   +1 more source

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source

Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Neuroendocrine neoplasms, which occur throughout the human body, as well as adrenocortical carcinoma and pheochromocytoma, which originate in the adrenal gland, are primarily classified as rare malignancies. Immunotherapy, including immune checkpoint inhibitors (ICIs), is generally not incorporated into the standard care protocols for these ...
Akihiro Ohmoto, Shunji Takahashi, Shigehisa Kitano   +2 more
wiley   +1 more source

Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain.
Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li   +4 more
wiley   +1 more source

Recent Advances in Microwave and Ultrasound Assisted Synthesis of Quinoline Derivatives as Anticancer Agents

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Green microwave‐ and ultrasound‐assisted synthesis enables the rapid, sustainable preparation of quinoline‐based anticancer agents with improved reaction efficiency, higher yields, and enhanced biological activity. ABSTRACT Quinoline derivatives represent a privileged class of heterocyclic compounds with remarkable structural diversity and broad ...
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Manjushree B V, Vipin K. Pandey, Shourya Pratap   +5 more
wiley   +1 more source

A POLE P286R‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer with histological and morphological properties of hepatocellular carcinoma, characterized by an aggressive course of the disease and unfavorable prognosis. Given the rarity of the pathology and the lack of unambiguous therapeutic protocols, descriptions of ...
Aleksey Chernev, Alina Kaurtseva, Ruslan Abasov, Rafael Enikeev, Nina Gegelia, Gulnara Abdrakova, Natalia Usman, Alexander Druy, Grigory Raskin   +8 more
wiley   +1 more source

Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR‐Negative Ovarian Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Progesterone induces rapid cellular responses in progesterone receptor (PR)‐negative ovarian cancer cells that are consistent with non‐genomic progesterone signaling. Vasohibin‐2 (VASH2), originally identified as a pro‐angiogenic factor, has recently been recognized as a tubulin carboxypeptidase involved in microtubule regulation ...
Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Eri Suizu, Kazuki Yamamoto, Akiyo Taneichi, Yuji Takei, Hiroaki Mizukami, Hiroyuki Fujiwara   +9 more
wiley   +1 more source

Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort. [PDF]

ESMO Open
Garcia-Carbonero R, Cote GM, Le Cesne A, Antón-Pascual B, Alonso-Gordoa T, Falcon A, Gil-Torralvo A, Martínez S, Kahatt C, Alfaro V, Zubiaur P, Jimenez J, Siguero M, Molina-Cerrillo J.   +13 more
europepmc   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains ...
Kenji Ikezawa, Toshihiro Imai, Ryoji Takada, Takuo Yamai, Nobuyasu Fukutake, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Kazuyoshi Ohkawa   +9 more
wiley   +1 more source